Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
Publication Year 2019-06-03,Volume 10,Issue #1,Page 2385
Journal Title
Nature Communications
Publication Type
Journal Article
Venetoclax is a first-in-class cancer therapy that interacts with the cellular apoptotic machinery promoting apoptosis. Treatment of patients suffering chronic lymphocytic leukaemia with this BCL-2 antagonist has revealed emergence of a drug-selected BCL-2 mutation (G101V) in some patients failing therapy. To understand the molecular basis of this acquired resistance we describe the crystal structures of venetoclax bound to both BCL-2 and the G101V mutant. The pose of venetoclax in its binding site on BCL-2 reveals small but unexpected differences as compared to published structures of complexes with venetoclax analogues. The G101V mutant complex structure and mutant binding assays reveal that resistance is acquired by a knock-on effect of V101 on an adjacent residue, E152, with venetoclax binding restored by a E152A mutation. This provides a framework for considering analogues of venetoclax that might be effective in combating this mutation.
Springer Nature
WEHI Research Division(s)
Structural Biology; Blood Cells And Blood Cancer; Chemical Biology
PubMed ID
Open Access at Publisher's Site
Terms of Use/Rights Notice
Refer to copyright notice on published article.

Creation Date: 2019-06-14 09:36:56
Last Modified: 2019-06-14 11:01:00
An error has occurred. This application may no longer respond until reloaded. Reload 🗙